April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Sodium Butyrate (NaB) Induces KAI-1 Expression And Apoptosis In Uveal Melanoma
Author Affiliations & Notes
  • Bruno F. Fernandes
    Ocular Pathology, McGill University, Montreal, Quebec, Canada
  • Shawn C. Maloney
    Ocular Pathology, McGill University, Montreal, Quebec, Canada
  • Emilia Antecka
    Ocular Pathology, McGill University, Montreal, Quebec, Canada
  • Sebastian Di Cesare
    Ocular Pathology, McGill University, Montreal, Quebec, Canada
  • Tamara Granner
    Ocular Pathology, McGill University, Montreal, Quebec, Canada
  • Miguel N. Burnier, Jr.
    Ocular Pathology, McGill University, Montreal, Quebec, Canada
  • Footnotes
    Commercial Relationships  Bruno F. Fernandes, None; Shawn C. Maloney, None; Emilia Antecka, None; Sebastian Di Cesare, None; Tamara Granner, None; Miguel N. Burnier, Jr., None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 1447. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Bruno F. Fernandes, Shawn C. Maloney, Emilia Antecka, Sebastian Di Cesare, Tamara Granner, Miguel N. Burnier, Jr.; Sodium Butyrate (NaB) Induces KAI-1 Expression And Apoptosis In Uveal Melanoma. Invest. Ophthalmol. Vis. Sci. 2011;52(14):1447.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To date, seven metastasis suppressor genes (MSG) have been recognized to suppress metastasis without affecting primary tumor growth: CD44, MAPK4, NM23-H1, NM23-H2, KISS1, BrMS1 and KAI-1. The suppression of KAI-1 in different types of cancer has been linked with decreased survival time due to an increased capability of cancer cells to invade tissues and to metastasize.We previously showed a strong correlation between decreased immunoexpression of KAI-1 and increased incidence of metastasis in uveal melanoma (UM). In the present study, we investigated the effect of KAI-1 overexpression after treatment of UM cell lines with Sodium Butyrate (NaB).

Methods: : Basal expression of KAI-1 was studied by confocal immunostaining and Western blot in 4 different UM cell lines (92.1, SP6.5, OCM-1 & MKT-BR). The 92.1 cell line was chosen to test the effects of sodium butyrate (NaB) in KAI-1 levels. A proliferation assay and TUNEL staining were performed at different concentrations of NaB. RT-PCR was used to confirm that the drug was able to cause an increase in KAI-1.

Results: : Under the confocal microscope, no significant differences in staining intensity were seen among the 4 studied cell lines. However, Western Blot revealed that 92.1, the most malignant one, had the lowest levels of KAI-1. Treatment of this cell line with NaB affected cell viability at the concentration of 1mM. Lower concentrations of the drug had no effect when comparing to the control. The observed decreased survival of the treated UM cell line correlated with induction of apoptosis, as seen by TUNEL staining. RT-PCR confirmed elevated levels of KAI-1 expression after treatment with 1mM but not with lower concentrations of the drug.

Conclusions: : We observed an inversed correlation between the levels of KAI-1 expression and metastatic potential in the UM cell line. The cell line with the highest metastatic potential (92.1) displayed the lowest concentration of KAI-1. NaB was able to increase the expression of this MSG and cause a reduction in the proliferation rates by inducing apoptosis. These results further substantiate the use of KAI-1 as a potential therapeutic target in the treatment of UM. Re-expression of KAI in high-risk patients might prevent disease progression and prolong disease-free survival.

Keywords: melanoma • apoptosis/cell death • drug toxicity/drug effects 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×